<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Video & Presentation library

Utility of a New Targeted Next Generation Sequencing Test for Liquid Biopsy Samples from Patients with NSCLC

Presented by: Dr. Hestia Mellert
Senior Director, Development
Biodesix

Presented Online June 26, 2020

Biodesix CEO Scott Hutton joins Jill Malandrino on Nasdaq TradeTalks

Biodesix CEO Scott Hutton joins Jill Malandrino on Nasdaq TradeTalks to discuss the company’s COVID-19 response and the impact to lung cancer care.

Presented Online June 23, 2020

Webinar Replay: Using a Blood-Based Biomarker in Patients with Pulmonary Nodules in a Real-World Observational Study

Presented by: Michael Pritchett, DO, MPH
Principal Investigator, ORACLE Study
Director, Thoracic Oncology
FirstHealth of the Carolinas at Pinehurst Medical Clinic, Pinehurst, NC

Presented Online on June 19, 2020

Webinar Replay: Real-World Performance of Blood-Based Host Immune Profiling in First-line Immunotherapy Treatment in Advanced Stage NSCLC

Presented by: Wallace Akerley, MD
Huntsman Cancer Institute
Chairman, Protocol Review & Monitoring Committee: Director, Lung Cancer Disease Center of Excellence, Medical Oncologist

Presented Online June 4, 2020

Webinar Replay: Blood-based Biomarkers for Evaluation of Pulmonary Nodules

Presented by: Gerard Silvestri, MD, MS FCCP
Lead author of the clinical validation study (PANOPTIC) for the Nodify XL2 blood-based lung nodule test

Presented Online May 18, 2020

Webinar Replay: Evaluating lung nodules during the COVID-19 pandemic using blood-based biomarkers

Watch a replay of the webinar from April 30, 2020
Presented by: Dr. Fayez Kheir, Dr. Steve Springmeyer, and Dr James Jett

Presented online May 1, 2020

Evaluating lung nodules during the COVID-19 pandemic using blood-based biomarkers

Nodify Lung™ testing integrates two blood-based lung nodules tests to help reclassify risk of malignancy. Watch a replay of a webinar where Biodesix Chief Medical Officers, Dr. James Jett and Dr. Steve Springmeyer, discuss the development and clinical validation of each test.

Presented Online May 5, 2020

How the Nodify XL2 Test Helps Identify Benign Lung Nodules is Relieving Patient Anxiety

Dr. Susan Garwood, M.D., Pulmonary and Advanced Bronchoscopy Lung Cancer Specialist with Centennial Medical Center in Nashville, part of the HCA TriStar division and Tresia Michael, LPN, Lung Nodule Coordinator for TriStar Health discuss how the Nodify XL2 test is relieving patient anxiety in their lung nodule clinic.

Presented Online on December 13, 2019

How Lung Nodule Clinics Use a Blood-Based Test to Help Identify Benign Lung Nodules

Dr. Susan Garwood, M.D., Pulmonary and Advanced Bronchoscopy Lung Cancer Specialist with Centennial Medical Center in Nashville, part of the HCA TriStar division and Tresia Michael, LPN, Lung Nodule Coordinator for Tri-Star Health discuss how they use the Nodify XL2 test in their clinic.

Presented Online on December 13, 2019

Three Physicians Give Insight into How Nodfiy XL2 Testing is Relieving Patient Stress and Helping Avoid Unnecessary Procedures

Three leading pulmonologists, Dr. Michael Pritchett, Dr. Krish Bhadra, and Dr. Mark Bowling provide insight into how the Nodify XL2™ test is helping relieve patient stress and how it may reduce invasive procedures on benign lung nodules by 40%. 

Presented Online December 12, 2019

Dr. Susan Garwood from TriStar Centennial Medical Center discusses lung nodule management

Nodify XL2™ is an easy outpatient blood-based test that answers a complex clinical problem. In just five days, this test has the potential to reduce unnecessary procedures in benign nodules by 40%. And at the heart of it all is a patient who will have the confidence to know that their physician now has a clear path forward.

Presented Online on November 4, 2019

A Look at the Future of Blood-Based Companion Diagnostics

Three leading experts in liquid biopsy diagnostic development, Gary Pestano, Viresh Patel and Dawne Shelton bring you insight into the developmental blueprint for blood-based IVDs. Novel case study data on the development of blood-based MSI, ALK, ROS and RET assays are discussed.

Presented Online on August 8, 2018

Applied Machine Learning in the Development of Immuno-Oncology Diagnostics

Dr. Mario Sznol presented on the complexity of the IO monotherapy and combination therapy clinical landscape and how a new era of proteomic based diagnostics will overcome unmet clinical needs. Dr. Heinrich Roder followed this by discussing how machine learning can be harnessed to design diagnostic classifiers, detailing how platforms infused with these capabilities can be taken forward as companion diagnostics.

Presented Online on November 15, 2017

Pre-Analytical Variable Considerations in the Development of Robust DNA and RNA ddPCR Assays

Learn how Streck blood collection tubes can help preserve valuable samples for liquid biopsy assay development. Hestia Mellert, PhD, Director of Molecular Product Development at Biodesix, describes pre-analytical considerations with the GeneStrat® genomic test.

Presented April 4, 2017 at American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

Victoria’s Story (A Patient's Experience with Biodesix Lung Reflex testing)

Victoria Bannister discovered that she had lung cancer during an unrelated doctor visit in early 2016. While seeking treatment she became frustrated with the long turnaround time on traditional tissue biopsy results. With the blood-based Biodesix Lung Reflex testing strategy, Victoria received her genomic and proteomic results in 72 hours and was able to quickly initiate treatment with a targeted therapy.

Specimen collection videos

View Specimen Collection Videos

Contact our team to learn more

Contact us